Dual Targeting of Akt and MAPK Pathways With Capivasertib and B-Raf Inhibitors Synergistically Suppresses Tumor Growth in B-Raf-Mutated Melanoma Models.

Abstract excerpt

Resistance to B-Raf inhibitors in melanoma poses a significant challenge to effective treatment. This study investigates the synergistic effects of capivasertib, an Akt pathway inhibitor, in combination with B-Raf inhibitors (vemurafenib and encorafenib) in B-Raf-mutated melanoma models. Combination index analysis demonstrated strong synergy between capivasertib and B-Raf inhibitors in melanoma cells. In...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Combined Chemotherapy Protocols
• Share to Drug Synergism